Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2008

Biological E. Gains Access to Production Technology from Heparinex and Choncept

  • Heparinex and Choncept entered into option and license agreements with Biological E. (BE), a biopharmaceutical company based in India. The agreement reportedly provides BE with an option for novel production technologies for both heparin- and chondroitin-related carbohydrate compounds.

    Heparinex is focused on development of novel recombinant synthesis of compounds for the anticoagulation market to replace the current heparin source of beef and other animal byproducts. Choncept works on the development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »